“With the commercial launch of ProFound Cloud, iCAD is enabling interoperability and access to Breast AI Solutions at enterprise scale, revolutionizing global access to cutting-edge AI solutions in breast health,” said
Powered by
“The healthcare landscape is shifting towards technology-as-a-service models, avoiding the pitfalls of investing in rapidly outdated hardware and software,” continued Brown. “As AI relies heavily on specialized hardware like graphical processing units (GPUs), setting up and upgrading both software and hardware becomes increasingly complex. Cloud-based solutions, like ProFound Cloud, address this challenge by providing Software as a Service (SaaS) to ensure that all customers access the latest technology without the initial hardware investment, support contracts, and constant updates. Moreover, ProFound Cloud provides facility administrators the ability to access the administration site, enabling them to update configurations and perform administrative tasks in multiple languages.”
“ProFound Cloud represents a significant advancement in the field of radiology, providing a seamless and standardized solution for accessing the latest AI technologies for our imaging network,” remarked
“ProFound Cloud is a prime example of how collaboration in healthcare technology drives innovation,” said
ProFound Cloud is designed to support patients, providers and partners while facilitating the management of diverse data types critical for comprehensive healthcare analysis. This includes 2D and 3D mammography images alongside all cancer images, in parallel, it stores limited images of benign, recall and normal cases. ProFound Cloud also manages ProFound Risk and Density assessment results, radiology and pathology reports and detection results, while ensuring seamless access to critical diagnostic information. Importantly, ProFound Cloud securely handles de-identified patient information and provider data, adhering to strict privacy and compliance standards. The comprehensive approach enables robust analytics for informed decision-making.
About
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com
Source:
2024 GlobeNewswire, Inc., source